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Abstract: Trypanosoma cruzi dysregulates the gene expression profile of primary human
cardiomyocytes (PHCM) during the early phase of infection through a mechanism which remains
to be elucidated. The role that small non-coding RNAs (sncRNA) including PIWI-interacting
RNA (piRNA) play in regulating gene expression during the early phase of infection is unknown.
To understand how T. cruzi dysregulate gene expression in the heart, we challenged PHCM with
T. cruzi trypomastigotes and analyzed sncRNA, especially piRNA, by RNA-sequencing. The parasite
induced significant differential expression of host piRNAs, which can target and regulate the genes
which are important during the early infection phase. An average of 21,595,866 (88.40%) of clean
reads mapped to the human reference genome. The parasite induced 217 unique piRNAs that were
significantly differentially expressed (q ≥ 0.8). Of these differentially expressed piRNAs, 6 were
known and 211 were novel piRNAs. In silico analysis showed that some of the dysregulated known
and novel piRNAs could target and potentially regulate the expression of genes including NFATC2,
FOS and TGF-β1, reported to play important roles during T. cruzi infection. Further evaluation of
the specific functions of the piRNAs in the regulation of gene expression during the early phase
of infection will enhance our understanding of the molecular mechanism of T. cruzi pathogenesis.
Our novel findings constitute the first report that T. cruzi can induce differential expression of piRNAs
in PHCM, advancing our knowledge about the involvement of piRNAs in an infectious disease model,
which can be exploited for biomarker and therapeutic development.
Keywords: Chagas disease; human cardiac myocytes; fibrosis; parasite pathogenesis; piRNAs;
piRNome; Trypanosoma cruzi

1. Introduction
The protozoan hemoflagellate parasite, Trypanosoma cruzi, is the causative agent of Chagas
heart disease. Originally endemic in Mexico and South America, this disease is now present in most
industrialized countries due to globalization and international travel [1–5]. Chagas disease causes severe
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morbidity and mortality worldwide. The refore, it is now considered a new global health challenge [6].
In the US, the disease burden and risk of various forms of autochthonous transmission, in states sharing
a border with Mexico and inland states, including in utero transmission, is higher than previously
reported [4,7,8]. This renders Chagas disease an unfolding tragedy in the US [3]. Approximately 30% of
T. cruzi infected individuals eventually present with incurable cardiac, neurological or gastrointestinal
tract pathologies. Specifically, Chagas disease patients can exhibit various cardiac pathologies in the
chronic stage of the infection, including myocarditis, myocardial hypertrophy, vasculitis and fibrosis,
ultimately leading to heart failure [6,9]. Chagas disease remains the world’s leading cause of infectious
myocarditis in afflicted individuals [10]. Chagasic cardiomyopathy’s severe health consequences are
accompanied by a significant economic burden [8]. Several studies using ex vivo and in vitro murine
cardiomyocyte culture models suggest that the parasite increases the expression of extracellular matrix
components, which could lead to remodeling of the heart [11–13]. Studies using cardiac tissues
from patients presenting with Chagasic cardiomyopathy suggest that genes associated with dilated
cardiomyopathy and inflammatory responses play a significant role in the onset of Chagasic cardiac
hypertrophy [14]. Additionally, studies have shown that T. cruzi can upregulate the expression of
genes involved in extracellular matrix function and mitochondrial energy metabolism, which play
a role in the development of cardiac hypertrophy [15,16]. Using primary human cardiomyocytes
(PHCMs), our laboratory demonstrated that T. cruzi induced differential expression of fibrogenic genes
during the early phase of infection; these genes include JunB, FOS, EGR1, EGR3 and SNAI1 [15].
We also showed that T. cruzi induced the expression of host thrombospondin-1 (TSP-1) during the
early phase of infection [17,18]. TSP-1 has been reported to play a role in the regulation of fibrotic
disorders through the activation of TGF-β, a profibrotic cytokine [19,20]. Others showed that active
TGF-β is very important during T. cruzi infection [21]. T. cruzi has been reported to dysregulate calcium
homeostasis to facilitate cellular infection [22]. Calcium binds to calmodulin (CaM) and activates the
phosphatase calcineurin and CaM Kinase II [23]. Furthermore, it was suggested that T. cruzi infection
induces an increase in endothelin-1 (ET-1) expression, which in turn plays an important role in the
activation of calcineurin [24]. Activated calcineurin dephosphorylates cytoplasmic nuclear factor of
activated T cells (NFATC), inducing its translocation into the nucleus, where it activates antiapoptotic
and hypertrophic target genes [23,25–27]. However, the molecular mechanisms by which the parasite
dysregulates gene expression in heart cells, especially during the early phase of cellular infection,
remain elusive. Reports in the literature suggest that RNA-mediated gene silencing achieved via
three small non-coding RNA (sncRNA) molecules—microRNAs (miRNAs), small interfering RNAs
(siRNAs), and P-element induced wimpy testis (PIWI)-interacting RNAs (piRNAs)—play important
roles in regulating gene expression by forming complexes with Argonaute proteins to recognize specific
target sequences [28]. Although piRNAs were previously thought to function only in maintaining
genome stability and integrity within the germline by silencing transposable elements (TE) [29],
they are now being considered to play important roles in regulating gene expression [30–32]. TEs can
be divided into two major classes. Class 1 (retrotransposons) is composed of long terminal repeat
(LTR) retrotransposons and non-LTR retrotransposons, which include long and short interspersed
nuclear elements (LINEs and SINEs), respectively. Class 2 elements (DNA transposons) also include
subclasses based on the mechanism of chromosomal integration [33]. Approximately 45% of the
mammalian genome is composed of retrotransposons which are known to play vital roles in neuronal
cells, germ cells, somatic cells and diseases like diabetes, cancer and heart disease among others [31,34].
TEs have long been found in the genome, where the cells coopt TE sequences for cellular processes [35].
piRNAs have been classified as silencing sncRNAs derived from small silencing RNAs (ssRNA) [36,37].
Some studies suggested that piRNAs may regulate gene transcription [36]. This gene regulatory
mechanism is thought to be similar to that of miRNAs [38].
Since piRNAs play essential roles in maintaining genomic stability and diversity,
their dysregulation could lead to mutagenesis and chromosomal rearrangement, causing genetic
mutations and diseases, including cancer [39,40]. Several piRNAs have been identified as biomarkers
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or potential targets in various cancers, including gastric cancer, hepatocellular carcinoma and colorectal
cancer, even though their complete scope of functions is still being discovered [41–44]. The re are
conflicting schools of thought about the function of piRNAs in immune regulation. For example,
tRNA-derived piRNAs expressed in monocytes can function as mediators of interleukin-4 (IL-4)
expression in immune cells to regulate the immune response [45]. It was suggested that piRNA-mediated
RNA interference (RNAi) potentiates an antiviral response in mosquito cells [46] while another study
concluded that the piRNA pathway is not necessary for antiviral defense in Drosophila [47].
In heart cells, piRNAs regulate AKT signaling through interaction with the PIWIL2 protein,
thereby playing an important role in cardiomyocyte proliferation and regeneration [31,32].
Patients presenting with myocardial infarction have a significantly elevated level of piR-2106027,
which has been suggested to be an important diagnostic marker for the disease [32,48]. Despite all these
important functions of known piRNAs, the molecular signature of the T. cruzi-induced piRNA profile
in human cardiomyocytes during the early phase of infection remains unknown. Here, we challenged
PHCM with T. cruzi and evaluated the piRNA expression profile (piRNome kinetics) during the
early phase of infection. We show that T. cruzi dysregulated the piRNA expression profile in PHCM
during the early phase of infection. We also observed that during the early phase of infection, T. cruzi
induced the differential expression of currently unreported putative piRNAs (novel piRNAs). In silico
analysis using miRanda and RNA22 showed that the novel piRNAs mapped to specific target regions
in genes coding for NFATC2, FOS and TGF-β1 reported to be important during the early phase
of T. cruzi infection. We built a framework that links known and putative novel piRNAs to their
potential molecular targets during the early infection process. Furthermore, we connect them in
biological networks to theoretically determine piRNA pathway-level interactions involved in T. cruzi
pathogenesis. This novel finding showing that a pathogen can dysregulate host piRNA expression
can be exploited for the development of molecular intervention strategies during the early phase of
T. cruzi infection.
2. Results
2.1. piRNAs are Differentially Expressed in PHCM during the Early Phase of T. cruzi Infection
To evaluate whether T. cruzi can dysregulate the expression of piRNAs in heart cells, we challenged
PHCM with invasive T. cruzi trypomastigotes Tulahuen strain, clone MMC20A. Purified sncRNA were
ligated, reverse transcribed and amplified by PCR. DNA-Nanoballs (DNB) generated were subjected
to RNAseq using the BGISEQ-500 sequencing platform. To analyze the clustering of the replicates
and their variance, we carried out a principle component analysis (PCA) of all sequenced sncRNAs,
which also include piRNAs. The analytical output showed that the biological replicates of the time
points in the experiment segregated independently of each other, as shown in the principal component
scatter plot. Principal component 1 (34.4% variance) and principal component 2 (13.2% variance)
showed that the samples from each group clustered together (Figure 1A). Furthermore, hierarchical
clustering, which also evaluates whether the gene expression profiles of sncRNAs at each time point
were specific, showed that replicates from each time point grouped together (Figure 1B). The one- and
two-hour cluster replicates are separate from the control replicate cluster, indicating that the differential
expression changes are substantial. Since piRNAs are generated from transposable element (TE)
sequences to target and repress mobile genetic elements, it would therefore be anticipated that piRNAs
can also be classified into TE families. Mapping of the differentially expressed piRNA sequences to
their genomic loci leads to their classification as DNA, LINE and LTR TE families. A large proportion
of the differentially expressed piRNAs originated from functionally active LINE retrotransposons,
representing 43% at the 1 h and 41% at 2 h time points (Figure 1C,D).
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2.2. T. cruzi Induces Differential piRNA Expression in PHCMs
2.2. T. cruzi Induces Differential piRNA Expression in PHCMs
To detect significant changes in the piRNA expression profile in PHCMs during the early phase
To detect significant changes in the piRNA expression profile in PHCMs during the early phase
of T. cruzi infection, we performed differential expression analysis using NOIseq [49]. We identified
of T. cruzi infection, we performed differential expression analysis using NOIseq [49]. We identified
217 unique piRNAs that were significantly differentially expressed (NOIseq probability of differential
217 unique piRNAs that were significantly differentially expressed (NOIseq probability of
expression, q ≥ 0.8). Among these, most were upregulated, with a minimum count of 104 unique
differential expression, q ≥ 0.8). Among these, most were upregulated, with a minimum count of 104
piRNAs at the 1 h time point, which increased to a maximum count of 188 unique piRNAs at the 2 h
unique piRNAs at the 1 h time point, which increased to a maximum count of 188 unique piRNAs at
time point. At both time points, 18 piRNAs were downregulated (Figure 2A). Supplemental Tables
the 2 h time point. At both time points, 18 piRNAs were downregulated (Figure 2A). Supplemental
S1 and S2 show the statistical values and sequence for each piRNA. Known piRNAs accounted for a
Tables S1 and S2 show the statistical values and sequence for each piRNA. Known piRNAs accounted
small portion of the differentially expressed piRNAs. Only two known piRNAs were substantially
for a small portion of the differentially expressed piRNAs. Only two known piRNAs were
differentially expressed at both time points (Figure 2B) among all six of these piRNAs that were
substantially differentially expressed at both time points (Figure 2B) among all six of these piRNAs
upregulated between the two time points. The majority of the significantly differentially expressed
that were upregulated between the two time points. The majority of the significantly differentially
piRNAs (q ≥ 0.8) are putative piRNAs; 94 were upregulated and 15 downregulated at both time
expressed piRNAs (q ≥ 0.8) are putative piRNAs; 94 were upregulated and 15 downregulated at both
time points (Figure 2C). Putative piRNAs accounted for all downregulated piRNAs. More piRNAs
were differentially expressed at the 2 h time point compared to the 1 h time point.
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points (Figure 2C). Putative piRNAs accounted for all downregulated piRNAs. More piRNAs were
differentially expressed at the 2 h time point compared to the 1 h time point.
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[54]. Our in silico analysis showed that both the known and novel piRNAs have target sites on all of
the AP-1 genes that we and others reported to be dysregulated by the parasite during the early phase
of cellular infection (Figure 3A–E). Five known piRNAs have target sites on NFATC2 and seven novel
piRNAs have potential target sites on NFATC2 (Figure 3A,B). Two known piRNAs differentially
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Our in silico analysis showed that both the known and novel piRNAs have target sites on all of the AP-1
genes that we and others reported to be dysregulated by the parasite during the early phase of cellular
infection (Figure 3A–E). Five known piRNAs have target sites on NFATC2 and seven novel piRNAs
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW
6 of 16
have potential target sites on NFATC2 (Figure 3A,B). Two known piRNAs differentially expressed
at 1 h target
while FOS
two novel
differentially
expressed at
both timeatpoints
target
FOS
expressed
at FOS
1 h target
while piRNAs
two novel
piRNAs differentially
expressed
both time
points
(Figure
3C,D).
Nine3C,D).
novel differentially
expressed piRNAs
target
the TGF-β1
six of them
both
target FOS
(Figure
Nine novel differentially
expressed
piRNAs
targetgene,
the TGF-β1
gene,atsix
of
time
points
(Figure
3E).
them at both time points (Figure 3E).

Figure 3.
3. piRNAs
piRNAsdifferentially
differentially
expressed
in PHCM
during
the phase
early phase
of T.
cruzi infection
expressed
in PHCM
during
the early
of T. cruzi
infection
mapped
mapped
specific
geneticmiRANDA
regions. miRANDA
RNA22 were
algorithms
used
to predict
to specifictogenetic
regions.
and RNA22and
algorithms
used towere
predict
target
bindingtarget
sites
binding
sites
known
and novel
piRNAs.
the genetic
cartoons,
exonsby
represented
blocks are
of known
andofnovel
piRNAs.
In the
geneticIncartoons,
exons
represented
blocks are by
connected
by
0
0
connected
by horizontal
linesintrons
representing
introns
while
the 5′ and 3′regions
untranslated
(UTRs) are
horizontal lines
representing
while the
5 and
3 untranslated
(UTRs)regions
are represented
as
thinner blocks
the extremities
gene, respectively.
NFATC2
gene cartoons
(30 gene
to 50 cartoons
orientation)
represented
asat
thinner
blocks at of
theeach
extremities
of each gene,
respectively.
NFATC2
(3′
showing
positions showing
where (A)positions
known piRNAs
and known
(B) novel
piRNAsand
that(B)
arenovel
differentially
to
5′ orientation)
where (A)
piRNAs
piRNAsexpressed
that are
at 1, 2 h or both
time points
be mapped,
respectively.
of FOSrespectively.
gene (50 –30 )
differentially
expressed
at 1,are2 predicted
h or bothtotime
points are
predicted Cartoons
to be mapped,
showing positions
where
(C) showing
known piRNAs
and
(D) novel
piRNAs
that areand
differentially
expressed
at
Cartoons
of FOS gene
(5′–3′)
positions
where
(C) known
piRNAs
(D) novel piRNAs
that
0)
1,
h or both timeexpressed
points areatpredicted
be time
mapped,
respectively.
(E) to
Cartoon
of TGF-β1
gene (30 –5
are2 differentially
1, 2 h or to
both
points
are predicted
be mapped,
respectively.
(E)
showing of
positions
differentially
expressed
piRNAs
are mapped.
Cartoon
TGF-β1where
gene (3′–5′)
showing
positionsnovel
where
differentially
expressed novel piRNAs are
mapped.

2.4. Biological Interaction Network of Differentially Expressed piRNA and AP-1 Transcription Factors during
the Early Phase of T. cruzi Infection
2.4. Biological Interaction Network of Differentially Expressed piRNA and AP-1 Transcription Factors
Inthe
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to Phase
understand
the Infection
molecular mechanisms that could be triggered in PHCM by piRNAs
during
Early
of T. cruzi
induced during the early phase of cellular infection by T. cruzi, we used the GeneMANIA algorithm to
In order to understand the molecular mechanisms that could be triggered in PHCM by piRNAs
construct biological interaction networks connecting known piRNAs to FOS and NFATC2 expanded
induced during the early phase of cellular infection by T. cruzi, we used the GeneMANIA algorithm
to one degree of molecular protein–protein interactions and visualized with Gephi (Figure 4A).
to construct biological interaction networks connecting known piRNAs to FOS and NFATC2
We show that the known piRNAs that were differentially induced can potentially target not only
expanded to one degree of molecular protein–protein interactions and visualized with Gephi (Figure
FOS and NFATC2 but also proteins that have the potential to interact with them. Additionally, in a
4A). We show that the known piRNAs that were differentially induced can potentially target not only
network similarly generated using the putative novel piRNAs that were also significantly differentially
FOS and NFATC2 but also proteins that have the potential to interact with them. Additionally, in a
network similarly generated using the putative novel piRNAs that were also significantly
differentially expressed, two-fold up- or downregulation (log2 ratio) with a probability of differential
expression q-value ≥ 0.8 was generated (Figure 4B). The novel piRNAs have predicted binding sites
on the AP-1 transcription factors and proteins that were expanded to one degree of interaction. The
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expressed, two-fold up- or downregulation (log2 ratio) with a probability of differential expression
q-value ≥ 0.8 was generated (Figure 4B). The novel piRNAs have predicted binding sites on the
AP-1 transcription factors and proteins that were expanded to one degree of interaction. The early
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We used the combinatorial probe-anchor synthesis (cPAS)-based BGISEQ-500 sequencing platform
that combines template enrichment using rolling circle amplification on DNB nanoarrays followed by
stepwise sequencing using polymerase. This approach is important because it applied linear DNA
amplification instead of exponential DNA amplification to make sequencing arrays, resulting in lower
error accumulation and sequencing bias, thereby improving the quality of our data [57,58].
Here, we show that the pathogen, T. cruzi, dysregulates the expression pattern of piRNAs in parasite
challenged PHCM. Before in-depth analysis, we conducted an NCBI BLAST search of the putative
piRNA sequences against the T. cruzi sequence database. We observed no significant alignments,
suggesting that the piRNAs are host-derived. Our bioinformatics analysis of the differentially expressed
piRNAs showed that piRNA experimental groups segregated independently of each other, the control
replicates clustering away from challenged PHCM replicates indicating that the differential expression
changes are substantial (Figure 1A,B). The data show a time-dependent piRNA expression profile
in PHCM in response to T. cruzi challenge. Many piRNAs are generated from TE, which were
hitherto classified as a group of “junk DNA” in the mammalian genome with unknown functions.
The generated piRNAs target and silence TE mRNAs, indicating that the piRNAs can be classified
into TE families, class 1 including long interspersed elements (LINE) and long terminal repeats (LTR)
and class 2 including DNA transposons [33,59]. The differentially expressed piRNAs, both known
and novel, reported in our study were classified into the TE subfamilies (Figure 1C,D). Of all the
dysregulated piRNAs, ~43% of them arise from LINEs after 1 h compared to 41% at 2 h. The proportion
of piRNAs arising from LTRs increased continuously from 39% at the 1 h time point to 42% at
the 2 h time point. This increasing percentage of dysregulated piRNAs originating from LTRs is
noteworthy. LTR regions typically contain promoters, and the insertion of mobile elements in these
regions could play a significant role in regulating the transcription of the neighboring genes or the
piRNAs themselves [60,61]. Thus, the high percentage of piRNAs originating from LTRs suggests an
important role in the regulation of gene expression during the early phase of T. cruzi infection.
More than 75% of the cumulative differentially expressed piRNAs induced by T. cruzi in
PHCM arise from LTRs and LINEs, suggesting that these regions are the primary source of piRNAs
during the early phase of T. cruzi infection compared to the piRNAs arising from DNA elements.
Our data show that during the early phase of T. cruzi infection of PHCM, the parasite induced
significant upregulation/downregulation of different piRNAs (Figure 2). This suggests that the parasite
dysregulates the host gene regulatory system by significantly altering the differential expression
of different piRNAs. The majority of the differentially expressed piRNAs that we report here are
putative (novel) piRNAs. The se novel piRNAs exhibit characteristics of previously reported canonical
piRNAs [31,62,63].
Previous studies showed that seed sequences are necessary for predicting piRNA–mRNA binding,
which suggests that piRNA targeting mimics that of miRNAs [38].
Due to the overlapping seed sequence positions of both piRNAs and miRNAs, we adapted
miRanda and RNA22 algorithms originally designed for predicting miRNA targeting, as shown by
others in our bioinformatic analysis [64].
Differentially expressed piRNAs and their predicted targets, NFATC2, FOS and TGF-β1, were
used to generate networks that linked the piRNAs to their target genes and expanded them to one
degree of freedom. In silico analysis showed that some of the differentially expressed piRNAs
(known and novel) can target genes that we and others reported to be dysregulated during the early
phase of T. cruzi infection (Figures 3, 4 and 5A). The piRNAs were also predicted to target sequences
on genes that were within one degree of interaction with the AP-1 transcription factors evaluated in
this study (Figures 4 and 5A). We also show that a novel piRNA (npiR46) can bind to target sequences
on both NFATC2 and FOS (Figure 4B). Our results show that novel piRNAs bind to target sequences
on TGFβ1 and only two novel piRNAs (npiR573 and 587) target genes with one degree of interaction
to TGFβ1 (Figure 5B). It has been suggested that piRNAs can regulate gene expression in a variety of
ways [65], but the exact molecular mechanisms by which these piRNAs regulate the genes reported
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in this study remain elusive and are under investigation in our laboratory. It is also not known if
a threshold number of piRNAs is required for the regulation of gene expression reported during
T. cruzi infection. Various reports have proposed piRNAs as biomarkers in cancer and predictors of
the pathology of colorectal and ovarian cancers [63,66]. However, the piRNA signature or the exact
role that these differentially regulated piRNAs play in the pathogenesis of T. cruzi infection remains
largely unknown. Taken together, our data show that during the early phase of infection, T. cruzi
trypomastigotes dysregulate and thereby cause significant differential expression of piRNAs in PHCM.
The se T. cruzi-induced piRNAs may serve as important biomarkers for the early phase of T. cruzi
infection. This is the first report showing that a pathogen can dysregulate host piRNA expression,
potentially leading to enhanced understanding of parasite-induced gene regulation, which is important
for the development of molecular intervention strategies during the early phase of T. cruzi infection.
4. Materials and Methods
4.1. Primary Human Cardiomyocyte Culture
Primary human cardiac myocytes (PHCM) were obtained from and cultured following
the manufacturer’s recommendations (PromoCell, Heidelberg, Germany). Briefly, the PHCM
were cultured in myocyte basal growth medium supplemented with the supplemental mix
(PromoCell, Heidelberg, Germany) containing fetal calf serum (0.05 mL/mL), recombinant human
epidermal growth factor (0.5 ng/mL), recombinant human basic fibroblast growth factor (2 ng/mL) and
recombinant human insulin (5 ug/mL). The cells were cultured in T75 flasks at 37 ◦ C in the presence
of 5% CO2 to approximately 80% confluency (approximately 4 × 106 cells) prior to being used in
our assays.
4.2. Parasite Culture and Infection Assays
Heart myoblast monolayers at 80% confluence, cultured in complete DMEM containing
5% glutamax, 10% fetal bovine serum, 1% each of penicillin/streptomycin, multivitamins and
MEM non-essential amino acids (Life Technologies, Carlsbad, CA, USA), were infected
with T. cruzi trypomastigotes.
Pure cultures of highly invasive T. cruzi trypomastigotes
(clone MMC 20A, Tulahuen strain) were harvested from the supernatant of infected heart myoblast
monolayers as previously described [67,68]. The parasites were washed with Hanks Balanced
Salt Solution (HBSS) and resuspended in PHCM growth medium without supplement at
1 × 107 parasites/mL. For the infection assays, confluent PHCM monolayers were starved in HBSS
containing 30 mM HEPES, followed by the addition of T. cruzi trypomastigotes in PHCM growth
medium without supplements at a ratio of 10 parasites per cell. Parasite-challenged PHCMs were
incubated for 1 and 2 h, respectively, in triplicate. To tal and small RNAs were extracted from all
samples. Mock-infected (media only) PHCMs served as control.
4.3. RNA Extraction and Quality Assessment
Control and parasite-challenged PHCM were washed with HBSS. The cells were lysed in QIAzol,
an RNA extraction lysis buffer and extracted with chloroform following the manufacturer’s instructions
(Qiagen, Valencia, CA, USA). The aqueous phase of the extract was mixed with an equal volume of
70% ethanol and passed through the RNeasy Mini spin column. The eluate, which contained small
RNA species, was mixed with 0.65 volumes of pure ethanol and passed through an RNeasy MiniElute
spin column. The column was washed with 80% ethanol and bound small RNA species were eluted
with RNase-free water essentially as described by the manufacturer (Qiagen). Large RNAs bound to
the RNeasy mini spin column were washed and eluted with RNase-free water as described by the
manufacturer (Qiagen). The quality of the purified RNA was analyzed using the Bioanalyzer 2100
system (Agilent Technologies, Santa Clara, CA, USA) to determine the RNA Integrity Number (RIN).
Samples with a RIN of at least 8 were considered for further analysis.
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4.4. RNA-Sequencing of sncRNA, Filtering and Expression Evaluation
Briefly, purified small RNA species ranging from 18 to 30 nt were ligated to the Illumina 30
adaptor and 50 adaptor. Ligation products were gel-purified, reverse-transcribed and amplified by
Rolling-Circle Replication (RCR). This linear amplification only copies the original DNA template
instead of copy-of-a-copy in order to make small, very high-density sequencing compacted templates
called DNA NanoBalls (DNBs). The DNBs were compacted on high-density patterned nanoarray
and sequenced by combinatorial Probe-Anchor Synthesis (cPAS), a sequencing chemistry technique
which is optimized for DNBseq. The combination of linear amplification and DNB technology
reduces the error rate while enhancing the signal. Smaller DNB spots with highly concentrated DNA
deliver significantly higher dye density than PCR cluster arrays, leading to higher signal-to-noise
for optimal imaging signal integrity. High-throughput sequencing (HTS) was conducted using the
BGISEQ-500 sequencing platform for small RNA (BGI, Cambridge, MA, USA) utilizing the NGS 2.0
DNBseq technology. The DNBseq sequencing technology (NGS 2.0) combines the power of DNA
Nanoballs (DNB), PCR-free Rolling Circle Replication, Patterned Nano Arrays and cPAS to deliver
a new level of data clarity and reliability. The BGISEQ-500 sequencing platform has comparable
sensitivity and accuracy in terms of quantification of gene expression, and low technical variability as
compared to the Illumina HiSeq platform [69,70]. High-throughput sequencing (HTS) was conducted
using the BGISEQ-500 sequencing platform for small RNA (BGI, Cambridge, MA, USA) [57,71].
In total, 30,001,700 raw HTS data were filtered by eliminating low-quality reads (less than 20 in Phred
quality score), as well as removing confounders such as adaptors and other contaminants including
missing 30 primers, 50 primer contamination and incomplete small non-coding RNA (sncRNA) reads of
less than 18 bp. Reads that met our analysis criteria were subjected to size filtration for piRNA to select
for sncRNA transcripts that were 25–30 bp in length and did not match any known miRNA or siRNA
sequences. Bowtie was used to map the reads to reference genomes [72]. The piRNA annotation
program (Piano) was used to predict known piRNAs via a support vector machine (SVM) algorithm
with transposon interaction informatics [73]. piRNA expression was determined using the standard
transcripts per kilobase million mapped (TPM) method [74].
4.5. Analysis of Differential piRNA Expression
The NOISeq method (version 3.34) was used to determine differentially expressed piRNAs.
Each time point was screened for significantly different piRNA expression compared to control by
calculating the log2 fold-change (M) and absolute differential value (D) between each pair of time points
to build a noise distribution model. A piRNA is counted as differentially expressed if M and D values
are likely to be higher than in noise. The significance threshold for differential piRNA expression was
set to fold-change ≥2 or ≤2 and a divergence probability ≥0.8. A probability of 0.8 is equivalent to an
odds value of 4:1, meaning that a given piRNA is 4 times more likely to be differentially expressed
than non-differentially expressed [49].
4.6. piRNA Target Prediction
Differentially expressed piRNAs were compared against hg38 RefSeq transcripts in miRanda [50]
using a high-stringency pairing score cutoff of ≥175, an energy cutoff of ≤−30 kcal/mol and a
requirement for exact seed region alignment. The prediction was also made in RNA22 [75] using a
high specificity setting.
4.7. Mapping of Biological Pathway Interactions
Pathway enrichment analysis was performed with WEBGESTALT web analysis software [76,77]
(http://bioinfo.vanderbilt.edu/wg2/) by mapping predicted piRNA targets to corresponding enriched
KEGG [78] (https://www.genome.jp/kegg/) pathways and conducting overrepresentation analysis.
Significance for pathway-level enrichment was defined as having an enrichment score false discovery
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rate (FDR) corrected p-value < 0.05. Biological interaction network construction was conducted with
the GeneMANIA algorithm [76,77] by querying multiple biological interaction databases including
GEO, BioGRID and EMBL-EBI. Predicted piRNA targets connected to the AP-1 transcription factor
family were set as starting seed nodes, and the network was then expanded to one degree of biological
interaction using GeneMANIA and visualized with Gephi [79] (https://gephi.org/).
4.8. Data Availability
All relevant data not presented in the manuscript are located in the SRA database: SRA accession:
PRJNA635217 (https://www.ncbi.nlm.nih.gov/sra/PRJNA635217).
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/24/
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